Published • loading... • Updated
AbCellera Stock Soars 35% on Successful Clinical Trial Result
The treatment cut hot flash frequency and severity after one dose, with 92 postmenopausal women enrolled and no serious adverse events reported.
- On Monday, AbCellera Biologics Inc. reported positive Phase 2 results for ABCL635, its experimental menopause treatment, sending shares soaring 35% by market close on August 10, 2026.
- The multicenter study enrolled 92 postmenopausal women to evaluate the non-hormonal, subcutaneous injection targeting the neurokinin 3 receptor , which regulates body temperature and alleviates moderate-to-severe hot flashes.
- ABCL635 participants experienced an 83% reduction in hot flash frequency versus 33% for placebo, while 58% reported less severe symptoms compared to 12% in the placebo group after four weeks.
- BMO Capital Markets analyst Evan Seigerman called the results "transformational," estimating a $6 billion global market opportunity and forecasting potential peak annual sales of about $2.3 billion for ABCL635.
- AbCellera plans to publish additional 12-week trial data later this year, though regulatory approval requires success in an expanded efficacy trial, a considerable challenge for late-stage drug candidates.
Insights by Ground AI
Podcasts & Opinions
14 Articles
14 Articles
Menopause drug cuts hot flashes in mid-stage trial, company says as shares rise
AbCellera said on Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up nearly 40 per cent in early morning trading.
·Toronto, Canada
Read Full Article
AbCellera stock soars on ‘off the chart’ trial results from hot flash treatment for menopausal women
Drug, called ABCL635, was found during an 92-person trial to deliver significant improvements in the frequency and severity of hot flashes compared to those who were taking a placebo
·Toronto, Canada
Read Full Article
Rutland Herald+2 Reposted by 2 other sources
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug 10, 2026-
Coverage Details
Total News Sources14
Leaning Left0Leaning Right1Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
C 86%
14%
Factuality
To view factuality data please Upgrade to Premium
